Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol

Lupin Ltd has entered into a License and Supply Agreement with Zentiva, k.s., for commercialization of Lupin's biosimilar Certolizumab Pegol.

Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories, whereas, Zentiva will oversee commercialization activities in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada.

The agreement has been entered with Zentiva, k.s. which is a leading company focused on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 30 countries across Europe and beyond.

This collaboration with Zentiva aims to expand Lupin's market reach and provide high-quality and cost-effective biosimilar to patients worldwide.

Shares of Lupin Limited was last trading in BSE at Rs. 1921.70 as compared to the previous close of Rs. 1977.40. The total number of shares traded during the day was 19321 in over 2621 trades.

The stock hit an intraday high of Rs. 1977.60 and intraday low of 1915.00. The net turnover during the day was Rs. 37208364.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals License Supply Agreement Zentiva Commercialization Biosimilar CertolizumabPegol